No CrossRef data available.
Article contents
Treatment of a patient suffering from schizophrenia and Becker muscular dystrophy with clozapine
Published online by Cambridge University Press: 24 June 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Comment & Critique
- Information
- Copyright
- Copyright © 2008 Blackwell Munksgaard
References
Kunkel, LM,
Hejtmancik, JF,
Caskey CT Speer, Aet al. Analysis of deletions in DNA in participants with Becker and Duchenne muscular dystrophy.
Nature 1986;322:73–77.
CrossRefGoogle Scholar
American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy.
Pediatrics 2005;116:1569–1573.
CrossRefGoogle ScholarPubMed
Emery, AE,
Skinner, R.
Clinical studies in benign (Becker type) X-linked muscular dystrophy.
Clin Genet 1976;10:189–201.
CrossRefGoogle ScholarPubMed
Reinders, J,
Parsonage, W,
Lange, D,
Potter, JM,
Plever, S.
Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service.
Aust N Z J Psychiatry 2004;38:915–922.
CrossRefGoogle Scholar
Koren, W,
Koren, E,
Nacasch, N,
Ehrenfeld, M,
Gur, H.
Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.
Clin Neuropharmacol 1998;21:262–264.
Google Scholar
Galletly, C.
Subjective muscle weakness and hypotonia during clozapine treatment.
Ann Clin Psychiatry 1996;8:189–192.
CrossRefGoogle ScholarPubMed
Abe, M,
Aria, M,
Mahera, K,
Arikawa, E,
Arahata, K.
A case of becker muscular dystropy with schizophrenic symptoms.
No To Shinkei 1990;42:1061–1066.
Google Scholar
Zatz, M,
Vallada, H,
Melo, MSet al. Cosegregation of schizophrenia with Becker muscular dystrophy: a susceptibility locus for schizophrenia at Xp21 or an effect of the dystrophin gene in the brain? J Med Genet 1993;30:131–134.
CrossRefGoogle ScholarPubMed
Melo, M,
Vierira, AH,
Passos-Bueno, MR,
Zatz, M.
Association of schizophrenia and Duchenne muscular dystrophy.
Br J Psychiatry 1993;162:711–712.
CrossRefGoogle ScholarPubMed
Kane, J,
Honigfeld, G,
Singer, J,
Meltzer, H.
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Arch Gen Psychiatry 45:789–796.
CrossRefGoogle ScholarPubMed
Reinders, J,
Parsonage, W,
Lange, D,
Potter, JM,
Pleaver, S.
Clozapine-related myocarditis in an Australian metropolitan service.
Aust N Z J Psychiatry 2004;38:915–922.
CrossRefGoogle Scholar
Caniato, RN,
Alvarenga, ME,
Garcia-Alcarez, MA.
Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine.
Aust N Z J Psychiatry 2007;40:691–697.
CrossRefGoogle ScholarPubMed
Galletly, C.
Subjective muscle weakness and hypotonia during clozapine treatment.
Ann Clin Psychiatry 1996;8;189–192.
CrossRefGoogle ScholarPubMed